Open AccessAn HCV ‐positive recipient of an HCV ‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
Author(s) -
Poordad Fred,
Lawitz Eric,
Gutierrez Julio A.,
Guerrero Juan,
Speeg Kermit,
Swenson Eugene S.
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.841
Subject(s) - medicine , sofosbuvir , hepatitis c virus , hepatitis c , daclatasvir , ribavirin , liver transplantation , gastroenterology , liver disease , cirrhosis , transplantation , immunology , virus
Key Clinical Message This case suggests that initiation of HCV therapy immediately after liver transplantation with well‐tolerated, all‐oral regimens may achieve a virologic cure in HCV ‐positive recipients, thus preventing post‐transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of HCV ‐positive donor livers, potentially including HCV ‐negative transplant recipients.